# Functional and Epigenomic Consequences of DNMT1 Variants in Inherited Neurological Disorders

**Authors:** Jun-Hui Yuan, Yujiro Higuchi, Masahiro Ando, Akiko Yoshimura, Satoshi Nozuma, Yusuke Sakiyama, Takashi Kanda, Masahiro Nomoto, Takeshi Nakamura, Yasuyuki Nobuhara, Hiroshi Takashima

PMC · DOI: 10.3390/ijms27031232 · International Journal of Molecular Sciences · 2026-01-26

## TL;DR

This paper explores how specific DNMT1 gene variants affect DNA methylation and neurological function, revealing distinct patterns of epigenetic changes in patients with inherited neurodegenerative disorders.

## Contribution

The study provides the first nanopore-based methylome analysis of DNMT1 variants and defines their domain-dependent functional and epigenomic effects.

## Key findings

- DNMT1 variants in the RFTS domain cause reduced protein expression, enzymatic activity, and cytosolic aggregation.
- Patients with p.Y511H show significantly reduced global 5mC levels compared to controls.
- Nanopore sequencing revealed distinct methylomic profiles and variant-specific epigenomic heterogeneity.

## Abstract

DNMT1 variants are linked to complex neurodegenerative syndromes, yet their variant-specific functional and epigenomic consequences remain poorly defined. DNMT1 variants were identified in eight patients using gene-panel or whole-exome sequencing. Functional effects were assessed by site-directed mutagenesis and transient expression in HEK293T cells. Genome-wide methylation profiling of peripheral blood leukocyte DNA was performed using Nanopore sequencing, enabling direct quantification of 5-methylcytosine (5mC). CpG island-level differential methylation and gene set enrichment analysis (GSEA) were conducted. Variants in the replication foci targeting sequence (RFTS) domain (p.Y511H, p.Y540C, p.H569R) exhibited reduced DNMT1 protein expression, decreased enzymatic activity, and cytosolic aggregation. Variants in the C-terminal catalytic domain (p.A1334V and p.P1546S) showed reduced protein expression with relatively mild enzymatic impairment. Patients carrying the p.Y511H variant demonstrated a significant reduction in global 5mC levels compared with controls. Principal component analysis revealed distinct methylomic profiles separating most patients from controls, with marked intra- and inter-familial heterogeneity. CpG island-level analysis identified a single significantly hypomethylated region in p.Y511H carriers, and GSEA revealed differential enrichment of multiple Gene Ontology biological pathways. This study defines domain-dependent functional effects of DNMT1 variants and provides the first nanopore-based methylome analysis, revealing variant-specific and heterogeneous epigenomic alterations.

## Linked entities

- **Genes:** DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786]
- **Proteins:** DNMT1 (DNA methyltransferase 1)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}
- **Diseases:** neurodegenerative syndromes (MESH:D020271), Neurological Disorders (MESH:D009461)
- **Chemicals:** 5-methylcytosine (MESH:D044503)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** p.H569R, p.A1334V, p.P1546S, p.Y540C, p.Y511H

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12898541/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12898541/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC12898541/full.md

---
Source: https://tomesphere.com/paper/PMC12898541